Changing frontline AML treatment patterns from 2013 to 2022
- 12 July 2023
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 132, 107354
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELNBlood, 2022
- Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid LeukemiaBlood, 2021
- Venetoclax Plus Azacitidine (VEN-AZA) Vs. Intensive Chemotherapy (IC) As Induction for Patients with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Records (EMR) Database in the United StatesBlood, 2021
- De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017Cancer, 2021
- Acute myeloid leukemia: current progress and future directionsBlood Cancer Journal, 2021
- An evaluation of no‐treatment decisions in patients with newly diagnosed acute myeloid leukemiaAmerican Journal of Hematology, 2020
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaNew England Journal of Medicine, 2020
- Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndromeLeukemia, 2018
- Acute Myeloid LeukemiaNew England Journal of Medicine, 2015
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blastsBlood, 2015